Although Candida spp. and Cryptococcus neoformans remain the most common causes of invasive opportunistic mycotic infection (14, 15, 35) , serious infections due to Aspergillus spp. and other filamentous fungi are emerging as prominent causes of infectious morbidity and mortality worldwide (5, 11, 13, 27) . Invasive aspergillosis occurs at a rate of 12.4 cases per million people per year in the United States (35). Dasbach et al. (4) estimated that invasive aspergillosis increased by approximately eightfold between 1976 and 1996, with over 10,000 cases and a cost of $548 million annually in the United States. Likewise, an expanding number of hyaline filamentous fungi (e.g. Fusarium, Acremonium, Penicillium, and Scedosporium species), Zygomycetes, and dematiaceous filamentous fungi (e.g., Bipolaris, Alternaria, and Exophiala species) pose additional threats to the ever-increasing population of immunocompromised hosts in hospitals and the community (13, 27, 29, 35) .
Although Candida spp. and Cryptococcus neoformans remain the most common causes of invasive opportunistic mycotic infection (14, 15, 35) , serious infections due to Aspergillus spp. and other filamentous fungi are emerging as prominent causes of infectious morbidity and mortality worldwide (5, 11, 13, 27) . Invasive aspergillosis occurs at a rate of 12.4 cases per million people per year in the United States (35) . Dasbach et al. (4) estimated that invasive aspergillosis increased by approximately eightfold between 1976 and 1996, with over 10,000 cases and a cost of $548 million annually in the United States. Likewise, an expanding number of hyaline filamentous fungi (e.g. Fusarium, Acremonium, Penicillium, and Scedosporium species), Zygomycetes, and dematiaceous filamentous fungi (e.g., Bipolaris, Alternaria, and Exophiala species) pose additional threats to the ever-increasing population of immunocompromised hosts in hospitals and the community (13, 27, 29, 35) .
Current diagnostic and therapeutic approaches fall short in addressing the problem of filamentous fungal infections (5, 13, 16) . Although amphotericin B remains the standard therapy for these infections, therapeutic outcomes are suboptimal (3, 13, 37, 39) . Clearly, there is a need for alternative antifungal agents to address these serious infections (7, 12, 13, 17, 38) .
Although ongoing antimicrobial surveillance systems have provided useful information regarding the spectrum of pathogens and the antifungal susceptibility of yeasts causing invasive fungal infections (1, 15, 30, 31, 33) , there is little, if any, such information for the filamentous fungi (29, 35) . Expansion of existing surveillance programs to include filamentous fungi will provide information regarding the frequency of various species causing invasive disease and in vitro susceptibility testing of these opportunistic pathogens against both new and established antifungal agents will provide data that may have important implications for antifungal drug treatment regimens in the appropriate clinical setting.
The SENTRY Antimicrobial Surveillance Program has documented the spectrum and activity of various antifungal agents against Candida spp. on a global scale since 1997 (6, (30) (31) (32) (33) . In January 2000, the SENTRY Surveillance Program was expanded to include monitoring of Aspergillus spp. and other filamentous fungi causing invasive mycoses in hospitalized patients. Clinical isolates from 16 different medical centers were sent to the University of Iowa for characterization, including antifungal susceptibility testing. In this study, we report the results of the first 12 months of filamentous fungal pathogen surveillance in the SENTRY Program (United States and Canada) and compare the in vitro activity of three new triazole antifungal agents, posaconazole, ravuconazole, and voriconazole, with that of itraconazole and amphotericin B using the National Committee for Clinical Laboratory Standards (NCCLS) M38-P microdilution method (23) . , and one isolate each of Acremonium sp., Biopolaris sp., Chrysosporium sp., Geotrichum sp., and Wangiella dermatitidis. All isolates were stored as spore suspensions in sterile distilled water at room temperature until they were used in the study. Before testing, each isolate was subcultured at least twice on potato dextrose agar (Remel, Lenexa, Kans.) to ensure its viability and purity.
MATERIALS AND METHODS

Organisms
Antifungal drugs. Posaconazole (Schering-Plough Research Institute, Kenilworth, N.J.), ravuconazole (Bristol-Myers Squibb, Wallingford, Conn.), voriconazole (Pfizer Pharmaceutical Group, New York, N.Y.), itraconazole (Janssen, Beerse, Belgium) and amphotericin B (Sigma Chemical Co., St. Louis, Mo.) were all obtained as reagent-grade powders from their respective manufacturers. Stock solutions were prepared in polyethylene glycol (posaconazole and itraconazole) and dimethyl sulfoxide (ravuconazole, voriconazole, and amphotericin B). All drugs were diluted in RPMI 1640 medium (Sigma Chemical Co.) buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS) buffer (Sigma) and dispensed into 96-well microdilution trays. The recommendations stated in NCCLS document M38-P were followed for the dilution of each antifungal agent (23) . Trays containing an aliquot of 0.1 ml in each well of appropriate drug solution (2ϫ final concentration) were sealed and stored at Ϫ70°C until they were used. The final ranges of drug concentrations tested were 0.008 to 8 g/ml for all five antifungal agents.
Susceptibility testing. MICs were determined by the NCCLS M38-P broth microdilution methodology (23) . Briefly, each isolate was grown on potato dextrose agar slants at 35°C for a period of 7 days. The fungal colonies were then covered with 1 ml of sterile 0.85% saline and gently scraped with a sterile pipette. The resulting suspensions were transferred to sterile tubes, and heavy particles were allowed to settle. The turbidity of the conidial spore suspensions was measured at 530 nm and was adjusted to obtain a final inoculum of 0.4 ϫ 10 4 CFU/ml. To determine the final inoculum, an appropriate dilution was performed and an aliquot (0.01 ml) was plated on potato dextrose agar (Remel). Plates were incubated at 30°C and were examined daily for the presence of fungal colonies. The microdilution trays were incubated at 35°C, and MICs were read at 48 h. Drug-free controls were included in each tray. Following incubation, MIC endpoints were interpreted with the aid of a reading mirror. Only wells that showed no growth (optically clear) or approximately 75% reduction in growth compared to that of drug-free controls were recorded as the MIC.
Quality control. Quality control was ensured by testing the following strains recommended in the NCCLS M38-P document (23) 
RESULTS AND DISCUSSION
The antifungal activities of posaconazole, ravuconazole, voriconazole, itraconazole, and amphotericin B against 198 isolates of Aspergillus spp. are shown in Table 1 . Posaconazole, ravuconazole, and voriconazole were all highly active against A. fumigatus (98 to 100% susceptible at a MIC of Յ1 g/ml), A. flavus (100%), A. terreus (100%), and Aspergillus spp. (91 to 94%). Among the 198 isolates of Aspergillus species tested, 98% were inhibited by Յ1 g/ml of posaconazole and voriconazole, followed by ravuconazole (92%), amphotericin B (89%), and itraconazole (72%). Notably, only 25% of A. terreus isolates were inhibited by Յ1 g/ml of amphotericin B compared to 92% of all other Aspergillus species.
The new triazoles were less active against the miscellaneous filamentous fungi ( Table 2 . Posaconzole and ravuconazole were more active than voriconazole against Rhizopus spp. (MIC 50 , 1 to 2 g/ml versus Ͼ8 g/ml, respectively).
Overall, 94% of the 239 filamentous fungi tested were inhibited by Յ1 g/ml of posaconazole, followed by voriconazole (91%), amphotericin B (89%), ravuconazole (88%), and itraconazole (70%) (data not shown).
These findings agree with those published earlier with smaller numbers of filamentous fungal isolates (8-10, 18, 19, 21, 25, 34) . We found that all three investigational triazoles were more active than itraconazole against all of the Aspergillus species tested. In almost every instance, the in vitro potencies of posaconazole, ravuconazole, and voriconazole were comparable to one another and slightly greater than that of amphotericin B. F78, 1995) ). Thus, the dosing regimens for these agents result in concentrations in plasma that exceed the MICs for 92 to 98% of Aspergillus species and 88 to 94% of all of the tested filamentous fungi (Tables 1 and  2) . We have also provided further evidence for the feasibility of the NCCLS M38-P broth microdilution method for comparing the activity of both new and established antifungal agents and for testing larger numbers of filamentous fungal isolates in the context of an antifungal surveillance program. Continued longitudinal surveillance efforts of this type using standardized susceptibility testing methods will provide the means with which to track the emergence of antifungal resistance over time among Aspergillus species and other filamentous fungal pathogens. The role of such testing in clinical decision-making, however, must await further studies establishing a correlation between in vitro MIC data and clinical outcome. Until such information is available, routine in vitro susceptibility testing of filamentous fungi as a prelude to clinical decision-making is not warranted (23) .
Recently, Espinel-Ingroff et al. (10) reported that the NCCLS M38-P microdilution method was able to reliably differentiate between susceptible and potentially resistant strains of Aspergillus species for itraconazole and possibly for the new triazoles as well. Espinel-Ingroff et al. (10) noted that crossresistance between itraconazole and the newer triazoles was not universal and may vary according to the strain of Aspergillus and the specific triazole being tested. Our results support these findings and are most notable for A. fumigatus, of which Ն95% of 114 isolates were inhibited by Յ0.5 g/ml of posaconazole, ravuconazole, and voriconazole compared to only 24% with itraconazole (Table 1) . In summary, we found that posaconazole, ravuconazole, and voriconazole all exhibit excellent in vitro activity against Aspergillus spp. and several less common filamentous fungi. These agents are more active than amphotericin B against Aspergillus spp. and offer important advantages over itraconazole in terms of spectrum and potency. Continued surveillance for emerging resistance and continued development of these exciting new agents is encouraged.
